A zeolite membrane structure includes a porous support, and a zeolite membrane. The zeolite membrane has a first zeolite layer located in a surface of the porous support, and a second zeolite layer located outside of the surface of the porous support and integrally formed with the first zeolite layer. The porous support has an outermost layer in which the first zeolite layer is located. An average thickness of the first zeolite layer is less than or equal to 5.4 micrometers. An average pore diameter of the outermost layer is greater than or equal to 0.050 micrometers and less than or equal to 0.150 micrometers.

The amorphous inorganic anion exchanger of the present invention is represented by Formula (1) and has an average primary particle size observed with an electron microscope of at least 1 nm but no greater than 500 nm and an NO.sub.3 content of no greater than 1 wt % of the whole:
BiO(OH)  Formula (1).

The amorphous inorganic anion exchanger of the present invention is represented by Formula (1) and has an average primary particle size observed with an electron microscope of at least 1 nm but no greater than 500 nm and an NO.sub.3 content of no greater than 1 wt % of the whole:
BiO(OH)  Formula (1).

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

Provided is a surfactant-free, single-step synthesis of delaminated aluminosilicate zeolites. The process comprises the step of heating a borosilicate zeolite precursor in a metal salt solution, e.g., an aluminum nitrate solution, zinc nitrate solution or manganese nitrate solution. The delaminated aluminosilicate zeolite product is then recovered from the solution.

Provided is a surfactant-free, single-step synthesis of delaminated aluminosilicate zeolites. The process comprises the step of heating a borosilicate zeolite precursor in a metal salt solution, e.g., an aluminum nitrate solution, zinc nitrate solution or manganese nitrate solution. The delaminated aluminosilicate zeolite product is then recovered from the solution.

A solid particulate composition useful in extracting a lithium salt from aqueous solutions, the composition comprising lithium, metal atoms, oxygen atoms, and at least one anionic species (X) selected from halide, nitrate, sulfate, carbonate and bicarbonate, all in a framework structure, wherein said metal atoms are selected from at least one of oxophilic main group metal and oxophilic transition metal atoms, provided that, if the metal atoms comprise aluminum atoms, then at least 10 mol % of said aluminum atoms are substituted with at least one metal atom selected from said at least one oxophilic main group and oxophilic transition metal atoms, other than aluminum, and wherein said lithium is present in said composition in an amount less than a saturated amount in order to permit extraction of lithium salt. Methods for extracting and recovering a lithium salt from an aqueous solution by use of the above-described composition are also described.

In an embodiment, the present disclosure pertains to a composition comprising a zeolite with high silica content. In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is 2:1. In some embodiments, the zeolite comprises Zeolite HOU-2 (LTA-type). In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is >3. In some embodiments, the zeolite comprises Zeolite HOU-3 (FAU type). In some embodiments, the zeolite is synthesized using a one-step method. In some embodiments, the zeolite is synthesized without the use of an organic structure-directing agent (OSDA). In some embodiments, the zeolite is synthesized without the use of post-synthesis dealumination. In some embodiments, the zeolite is synthesized without the use crystal seeds. In some embodiments, the zeolite is used in commercial ion exchange. In some embodiments, the zeolite is used for catalysis reaction. In some embodiments, the zeolite is highly thermostable.

In an embodiment, the present disclosure pertains to a composition comprising a zeolite with high silica content. In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is 2:1. In some embodiments, the zeolite comprises Zeolite HOU-2 (LTA-type). In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is >3. In some embodiments, the zeolite comprises Zeolite HOU-3 (FAU type). In some embodiments, the zeolite is synthesized using a one-step method. In some embodiments, the zeolite is synthesized without the use of an organic structure-directing agent (OSDA). In some embodiments, the zeolite is synthesized without the use of post-synthesis dealumination. In some embodiments, the zeolite is synthesized without the use crystal seeds. In some embodiments, the zeolite is used in commercial ion exchange. In some embodiments, the zeolite is used for catalysis reaction. In some embodiments, the zeolite is highly thermostable.